Skip to main content
SpringerLink
Log in

NC 100100

DD 723, NUS, Sonazoid

  • Adis R&D Profile
  • Published:
Drugs in R & D Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II

Notes

  1. This profile has been selected from R&D Insight™, a pharmaceutical intelligence database produced by Adis International Ltd.

References

  1. Towart R, Karlsson JOG, Moen O, et al. NC100100 has no negative effects on experimental infarct size in dogs. Naunyn- Schmiedeberg’s Arch Pharmacol 358 (Suppl 2): 616 (Poster), No. 1, 1998

    Google Scholar 

  2. Yao JF, Teupe C, Takeuchi M, et al. Quantitative 3-dimensional contrast echocardiographic determination ofmyocardial mass at risk and residual infarct mass after reperfusion: experimental canine studies with intravenous contrast agent NC100100. J Am Soc Echocardiogr 13: 570–581, Jun 2000

    Article  PubMed  CAS  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

NC 100100. Drugs R&D 3, 210–211 (2002). https://doi.org/10.2165/00126839-200203030-00016

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00126839-200203030-00016

Keywords

Search

Navigation